1.         Describe how the integration of biomarkers is transforming traditional cognitive assessment in Alzheimer’s disease.

2.         Compare the roles of AD Biomarkers and Neuropsychological Testing in diagnosis, prognosis, and treatment planning, including their strengths and limitations.

3.         Discuss barriers such as test length, throughput efficiency, and diagnostic complexities in initiating timely treatment.

4.         Address accessibility, accuracy, ethical concerns, and challenges in combining biomarker data with cognitive testing.